MuRF2 regulates PPARγ1 activity to protect against diabetic cardiomyopathy and enhance weight gain induced by a high fat diet by He, J et al.
He et al. Cardiovasc Diabetol  (2015) 14:97 
DOI 10.1186/s12933-015-0252-x
ORIGINAL INVESTIGATION
MuRF2 regulates PPARγ1 activity 
to protect against diabetic cardiomyopathy 
and enhance weight gain induced by a high fat 
diet
Jun He1,2†, Megan T Quintana3†, Jenyth Sullivan4, Traci L Parry5, Trisha J Grevengoed6, Jonathan C Schisler5,7, 
Joseph A Hill8, Cecelia C Yates9, Rudo F Mapanga10, M Faadiel Essop10, William E Stansfield3, James R Bain11,12, 
Christopher B Newgard11,12, Michael J Muehlbauer11, Yipin Han13, Brian A Clarke14 and Monte S Willis1,5*
Abstract 
Background: In diabetes mellitus the morbidity and mortality of cardiovascular disease is increased and represents 
an important independent mechanism by which heart disease is exacerbated. The pathogenesis of diabetic cardio-
myopathy involves the enhanced activation of PPAR transcription factors, including PPARα, and to a lesser degree 
PPARβ and PPARγ1. How these transcription factors are regulated in the heart is largely unknown. Recent studies have 
described post-translational ubiquitination of PPARs as ways in which PPAR activity is inhibited in cancer. However, 
specific mechanisms in the heart have not previously been described. Recent studies have implicated the muscle-
specific ubiquitin ligase muscle ring finger-2 (MuRF2) in inhibiting the nuclear transcription factor SRF. Initial studies of 
MuRF2−/− hearts revealed enhanced PPAR activity, leading to the hypothesis that MuRF2 regulates PPAR activity by 
post-translational ubiquitination.
Methods: MuRF2−/− mice were challenged with a 26-week 60% fat diet designed to simulate obesity-mediated 
insulin resistance and diabetic cardiomyopathy. Mice were followed by conscious echocardiography, blood glucose, 
tissue triglyceride, glycogen levels, immunoblot analysis of intracellular signaling, heart and skeletal muscle morpho-
metrics, and PPARα, PPARβ, and PPARγ1-regulated mRNA expression.
Results: MuRF2 protein levels increase ~20% during the development of diabetic cardiomyopathy induced by high 
fat diet. Compared to littermate wildtype hearts, MuRF2−/− hearts exhibit an exaggerated diabetic cardiomyopathy, 
characterized by an early onset systolic dysfunction, larger left ventricular mass, and higher heart weight. MuRF2−/− 
hearts had significantly increased PPARα- and PPARγ1-regulated gene expression by RT-qPCR, consistent with MuRF2’s 
regulation of these transcription factors in vivo. Mechanistically, MuRF2 mono-ubiquitinated PPARα and PPARγ1 
in vitro, consistent with its non-degradatory role in diabetic cardiomyopathy. However, increasing MuRF2:PPARγ1 
(>5:1) beyond physiological levels drove poly-ubiquitin-mediated degradation of PPARγ1 in vitro, indicating large 
MuRF2 increases may lead to PPAR degradation if found in other disease states.
Conclusions: Mutations in MuRF2 have been described to contribute to the severity of familial hypertrophic cardio-
myopathy. The present study suggests that the lack of MuRF2, as found in these patients, can result in an exaggerated 
diabetic cardiomyopathy. These studies also identify MuRF2 as the first ubiquitin ligase to regulate cardiac PPARα and 
PPARγ1 activities in vivo via post-translational modification without degradation.
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Background
The leading cause of morbidity and mortality worldwide 
is cardiovascular disease [1], frequently accompanied 
by the dysregulation of fatty acid metabolism associated 
with diabetes mellitus (DM). In the presence of DM, 
the morbidity and mortality of cardiovascular disease 
is increased and represents an important independent 
mechanism by which heart disease is exacerbated [2, 3]. 
The characteristic disturbances in myocardial energy and 
fatty acid homeostasis found in DM are mediated pri-
marily by a network of peroxisome proliferator-activated 
receptor (PPAR) transcription factors that direct the 
energy substrates and determine the myocardial home-
ostasis [4, 5]. Chronic activation of PPARs in DM leads 
to an increase in free fatty acid uptake/oxidation corre-
sponding to the level of insulin resistance in cardiomyo-
cytes [6]. The increased reliance on fatty acid metabolism 
decreases the efficiency of the heart by increasing the 
amount of oxygen needed to create the needed energy, 
resulting in lipotoxicity [7]. The ligand (fatty acid)-driven 
activation of PPAR transcription factors regulate the 
expression of target genes, which control the uptake, 
utilization, oxidation, and storage of fatty acids [8]. In 
the heart, all three PPAR receptors have been identified 
(PPARα, PPARδ/β, and PPARγ) and implicated in cardio-
vascular disease [9].
Insulin resistance is a risk factor for left ventricular 
(LV) dysfunction and heart failure and is one of the hall-
marks of type 2 DM [10]. Despite hyperinsulinemia and 
hyperglycemia, the diabetic heart relies almost exclu-
sively on fatty acid utilization [11] in both rodent models 
and humans with excessive fat intake [12]. The resulting 
increase in fatty acid increases reaction oxygen species 
(ROS) production and accumulation of lipid intermedi-
ates [e.g. diacylglycerol (DAG)], which have a profound 
impact on insulin signaling [13]. The c-JUN NH 2-termi-
nal kinase (JNK) and inhibitor κB kinase (IKK), activated 
by ROS [14, 15], parallel activation of protein kinase C 
(PKC) by DAG, all of which act to down-regulate insulin 
action by preventing insulin receptor substrate-1 (IRS-
1) phosphorylation [13]. High systemic fatty acid uptake 
also inhibits Akt signaling, resulting in the downregula-
tion of forkhead box O (FOXO) transcription factors 
[16, 17], while the increased ROS activate nuclear factor 
kappa B (NF-κB) [18], both of which contribute to the 
development of cardiac hypertrophy [12, 19].
The muscle ring finger (MuRF) family of ubiqui-
tin ligases, including MuRF2 (Trim55), was identified 
in 2001 as a highly homologous group of proteins that 
homo- and hetero-dimerize through their coiled-coil 
domains [20]. This family of proteins is found in striated 
muscle, including skeletal and cardiac myocytes and was 
originally found to be a critical regulator of microtubule 
assembly during models of skeletal muscle development 
[21, 22]. Recent studies have detailed the importance 
of MuRF2 in the earliest stages of skeletal muscle dif-
ferentiation and myofibrillogenesis in  vivo [23]. In the 
present study, we identify that endogenous cardiomyo-
cyte MuRF2 inhibits multiple PPAR isoforms, primar-
ily PPARγ (but to a lesser extent PPARδ/β and PPARα). 
Given the relative importance of PPARs in the develop-
ment of diabetic cardiomyopathy and the downstream 
pathophysiology, we challenged MuRF2−/− mice to a 
60% fat diet-induced cardiomyopathy recently described 
[24, 25]. With PPAR signaling at the center of regulat-
ing fatty acid oxidation and mediating the pathogenesis 
of type 2 DM induced cardiomyopathy, we hypothesized 
that if MuRF2−/− hearts had enhanced PPAR signal-
ing, they would undergo an accelerated cardiomyopathy 
due to MuRF2’s direct regulation of PPAR activity. We 
identified that MuRF2−/− hearts undergo an exagger-
ated diabetic cardiomyopathy, resulting from MuRF2’s 
multi-ubiquitination of PPARα and PPARγ1 in a protea-
some-independent (non-degradatory) mechanism. These 
studies identify the first ubiquitin ligase to regulate PPAR 
via post-translational ubiquitination.
Methods
Animals and high fat diet‑induced diabetic 
cardiomyopathy model
All experiments described used age-matched mice or 
littermates, male and female. All experiments were 
approved by the Institutional Animal Care and Use 
Committee (IACUC) review boards at the University of 
North Carolina and were performed in accordance with 
federal guidelines. Ten week-old MuRF2−/− and strain-
matched wild type mice [26] were fed a high fat diet (60% 
fat, 20% protein, and 20% carbohydrates) for 26 weeks as 
previously described [24]. Baseline body weight, blood 
glucose, serum insulin, serum triglyceride, and total cho-
lesterol levels along with cardiac function were obtained 
prior to starting the diet. Body weight, blood glucose, 
and serum insulin levels measured every 2 weeks; echo-
cardiography was performed every 3 weeks. An MRI was 
performed at baseline, 6, 12, and 22 weeks to detect body 
composition changes. After 26  weeks, mice were anes-
thetized with isoflurane, euthanized with cervical spine 
dislocation, and heart, liver, gastrocnemius, soleus, and 
tibialis anterior muscles were collected in cryovials, flash 
frozen, and stored at −80°C.
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Mouse echocardiography
Conscious transthoracic echocardiography was per-
formed on mice at the indicated time points using a Visu-
alSonics Vevo 2100 ultrasound biomicroscopy system 
(VisualSonics, Inc., Toronto, Ontario, Canada). Investiga-
tors were blinded to mouse genotype. Two-dimensional 
M-mode echocardiography was performed in the par-
asternal long-axis view at the level of the papillary muscle 
on loosely restrained mice. Anterior and posterior wall 
thickness was measured as distance from epicardial to 
endocardial leading edges. Left ventricular internal diam-
eters were also measured. Left ventricular systolic func-
tion was assessed by ejection fraction (LV EF%  =  [(LV 
Vol; d-LV Vol; s/LV Vol; d) × 100] and fractional shorten-
ing (%FS = [(LVEDD − LVESD)/LVEDD] × 100). Meas-
urements represent the average of three cardiac cycles 
from each mouse.
Body composition measurement
Conscious low-resolution nuclear magnetic resonance 
imaging was used to measure body composition of each 
mouse at baseline, 6, 12, and 22 weeks using an EchoMRI 
3-in-1 Body Composition Analyzer for Live Small Ani-
mals (Mice) (EchoMRI, LLC, Houston, TX, USA) [27]. 
Body fat and lean body mass was then calculated as a 
proportion of total body weight collected just prior to 
analysis as previously described [28].
Blood collection, serum separation, and methods 
for glucose, insulin, triglyceride, and total cholesterol 
measurements
After overnight fast, ~200 µl whole blood was collected 
by submandibular vein lancet bleed (glucose) or bra-
chial sinus puncture (remaining assays). One microliter 
whole blood was analyzed via glucometer (PrecisionX-
tra, Abbott Diabetes Care Inc., Alameda, CA, USA) and 
test strip (Abbott Diabetes Care Ltd., Witney, Oxon, UK). 
Blood collected in serum separator tubes for the remain-
ing tests was incubated on ice for 90 min, and centrifuged 
at 1,600×g (20 min at 4°C). Insulin levels were measured 
using the Insulin Enzyme Immunoassay Kit (Cayman 
Chemical, Cat. #589501, Ann Arbor, MI 48108, USA) 
according to the manufacturer’s instructions as previ-
ously described [29]. Serum triglyceride and cholesterol 
levels were measured using an automated chemical ana-
lyzer (Vitro 350, OrthoClinical Diagnostics Company, 
Rochester, NY, USA).
Fatty acid extraction and triglyceride assay
Fatty acid extraction and tissue triglyceride concentra-
tions were determined on flash frozen heart tissue, liver 
tissue, and skeletal tissue as previously described [30]. 
Briefly, 25–50  mg of heart, liver and skeletal muscle 
was homogenized 15–30  s with a bladed homogenizer 
(Power Gen 125, Cat. #14-261, setting 6, Fisher Scien-
tific, Inc., Pittsburgh, PA, USA) in 10× (v/w) ice cold 
lysis buffer [20 mM Tris base, 1% Triton-X100, 50 mM 
NaCl, 250  mM NaF, 5  mM Na4P2O7-10H2O, 1 tab-
let protease inhibitor (Roche Inc., Cat. #11836153)] 
and incubated at 4°C for 1 h. Two hundred microliters 
of homogenate was transferred to chloroform resist-
ant tubes, mixed with 0.4  ml methanol and 0.8  ml 
chloroform, placed on the rocker at 4°C for at least 
30  min. Potassium chloride (0.24  ml 0.88% KCl) was 
added, samples vortexed, and centrifuged at 1,000×g 
for 15 min at 4°C. The bottom layer of CHCl3 was then 
transferred and this process was repeated with another 
0.8  ml of chloroform and the combined CHCl3 layers 
were then dried under N2. One hundred microliters of 
a tert-butanol:methanol:Triton X-100 solution (3:1:1, 
v/v/v) was added to each tube and samples were stored 
at −20°C. Glycerol standard 2.5 mg/dl (Sigma, Inc., Cat. 
#G1394), free glycerol reagent (Sigma Aldrich, Inc., Cat. 
#F6428) and triglyceride reagent (Sigma Aldrich, Inc., 
Cat. #T2449) were used to measure triglyceride concen-
trations. Five microliters of the samples were added to 
a 96-well plate. Working reagent was added to the sam-
ples (four volumes of free glycerol reagent: 1 volume of 
triglyceride reagent). This was left to incubate, rocking, 
at room temperature for 15 min. Then absorbance was 
measured per sample at 540  nm using the Clariostar 
High Performance Multimode Microplate Reader (BMG 
LABTECH, San Francisco, CA, USA) and normalized to 
tissue weight.
Tissue glycogen assay (acid hydrolysis method)
Tissue glycogen was measured from heart, liver and skel-
etal muscle using a colorimetric tissue glycogen assay 
kit (Sigma, Inc., Cat. #G3293) as previously described 
[31]. Briefly, 15–25  mg of tissue was powdered in liq-
uid nitrogen, collected in a pre-chilled 2 ml tube, 0.5 ml 
1 N HCl added, then homogenized with bladed homog-
enizer (Fisher Scientific, Power Gen 125, Cat. #14-261, 
setting 6, Pittsburgh, PA, USA) under a hood. The result-
ing homogenate (100 µl) was quickly added to 100 µl 1 N 
NaOH and kept on ice until heated in HCl at 95°C for 
90  min, mixing every 30  min, cooled to RT and 0.4  ml 
1 N Na OH was added to neutralize the sample. After the 
sample was centrifuged at 14,000×g for 10 min at RT, the 
supernatant was used for glucose analysis using a hexoki-
nase-dependent assay kit (Sigma, Inc., Cat. #G3293) 
according to the manufacturer’s instructions. Briefly, 
10 μl (liver) or 20 μl (heart and gastrocnemius) of super-
natant was put into a 96-well plate, mixed with 200 μl of 
reagent, incubated at room temperature for 15 min, and 
the absorbance was measured at 340 nm.
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Cell culture
Cos-7 and HEK293 cells were cultured in DMEM con-
taining 10% FBS, 100  unit/ml penicillin and 0.1% mg/
ml streptomycin. HL-1 cardiomyocytes were cultured in 
supplemented Claycomb medium containing 10% FBS, 
100 unit/ml penicillin, 0.1% mg/ml streptomycin, 0.1 mM 
norepinephrine and 2  mM  l-glutamine. All cells were 
incubated at 37°C in a 5% CO2 humidified atmosphere.
Confocal microscopy
HL-1 cardiomyocytes (2.5  ×  105/well/50% confluent) 
plated on Gelatin/Fibronectin were co-transfected with 
Flag-PPARγ1 and HA-MuRF2 using Lipofectamine 
LTX & PLUS (Invitrogen, lot#1397274) according to the 
manufacturer’s instructions. The ratios of LTX/DNA 
and PLUS/DNA (μl/μg) both were 2:1. Equal amounts 
of DNA were transfected by adjusting with empty vec-
tors. After 48 h of transfection, the cells were fixed with 
4% paraformaldehyde and blocked in 5% goat serum with 
0.2% TritonX-100 at room temperature for 1  h. Cells 
were incubated with Rb anti-Flag (Sigma F7425, 1:100, 
4°C, overnight or Ms anti-HA (Sigma H9658, 1:100, 4°C, 
overnight). Cells were washed and incubated with anti-
Ms 488 to detect HA-MuRF2 (Invitrogen, 1:1,000) or 
anti Rb 568 (Invitrogen, 1:1,000) for 1 h at room temper-
ature. The membranes were cut into 1 ×  1  cm sections 
and mounted to glass slides with Fluoro-Gel Anti-fade 
mounting medium with DAPI (EMS, Hatfield, PA Cat. 
#17983-20) and analyzed by fluorescent confocal micros-
copy using a Zeiss CLSM 710 Spectral Confocal Laser 
Scanning Microscope.
RNA isolation and quantitative PCR analysis 
of PPAR‑regulated gene expression
Total RNA was isolated using TRIzol reagent according 
to the manufacturer’s protocols (Life Technologies, Inc., 
Cat. #15596-026). Approximately 25  mg of cardiac ven-
tricular tissue was put into TRIzol reagent and homog-
enized on ice (Fisher Scientific, Power Gen 125, setting 
5). Total mRNA expression was determined using a two-
step reaction. cDNA was made from total RNA using the 
iScript™ Reverse Transcription Supermix for RT-qPCR 
kit (Cat. #170-8841, BIO-RAD), with a total volume of 
20 µl per reaction. The complete reaction mix was incu-
bated in an Eppendorf Cycler (Hamburg, Germany) 
using the following protocol: priming 5  min at 25°C, 
reverse transcription 30  min at 42°C, RT inactivation 
5 min at 85°C. PCR products were amplified on a Roche 
Lightcycler 480II system using cDNA, Taqman Probes 
(Applied Biosciences™), and Lightcycler 480 Probe 
Master Mix 2X (Cat. #04 707 494 001). The TaqMan 
probes used in this study are Mm00430615_m1 (ACC1), 
Mm00443579_m1 (ACOX1), Mm00475794_m1 (ADRP), 
Mm00599660_m1 (LCAD), Mm00431611_m1 (MCAD), 
Mm00440939_m1 (PPARα), Mm01305434_m1 (PPARβ), 
Mm00443325_m1 (PDK4), Mm00487200_m1 (CPT1b), 
Mm00441480_m1 (Glut1, Slc2a1), Mm01245502_m1 
(Glut4, Slc2a4), Mm01309576_m1 (PFK), Mm00432403_
m1 (CD36, FAT), Mm01185221_m1 (MuRF1, Trim63), 
and Mm01292963_g1 (MuRF2, Trim55), Hs99999901_
s1 (18S), Mm00440359_m1 (α-MHC, Myh6), 
Mm00600555_m1 (β-MHC, Myh7), Mm01255747_g1 
(ANP), Mm00435304_g1 (BNP), Mm00808218_g1 (SK 
α-actin) (Applied Biosystems, Inc., Foster City, CA, 
USA). Assay of PPARγ1 was performed using the Roche 
Universal Probe technology, including forward primer 
(gggctgaggagaagtcacac) and reverse primer (gggctgagga-
gaagtcacac) in conjunction with UPL probe #92 (Roche, 
Inc., Cat. #04692098001). Samples were run in triplicate 
and relative mRNA expression was determined using 18S 
as an internal endogenous control. RNase-free water, 2× 
Master Mix, Taqman Probe or Roche UPL primer and 
probe, and cDNA were used for each reaction.
Western blot
Western analysis of ventricular tissue was performed 
on lysates created from ~25 mg tissue placed in 1× Cell 
Signaling Lysis Buffer (for 10 ml: 1 ml 10× Cell Signaling 
Lysis Buffer, Cat. #9803S; 0.108  g β-glycerol phosphate, 
Sigma, Cat. #G6251; 1 tablet protease inhibitor, Roche 
Cat. #11 836 153 001; 100 μl 100X phosphatase inhibitor 
cocktail, Roche Cat. #04 906 837 001) and was homog-
enized on ice (Fisher Scientific, Power Gen 125, setting 5) 
for ~15–20 s. The homogenate was incubated on ice for 
30 min, centrifuged at 4°C, ×16,000×g for 15 min and the 
supernatant stored at −80°C. Protein concentration was 
determined using the Bio-Rad DC Protein Assay Reagent 
Package (Bio-Rad Laboratories, Inc., Hercules, CA, Cat. 
#500-0116). Proteins (30–50  μg/lane) were resolved on 
NuPAGE Bis–Tris or Tris–Acetate 10 well gels. Mouse 
anti-NFκB p65, rabbit anti-phospho-NFκB p65 (Ser536), 
rabbit anti-phospho-NFκB p65 (Ser468) were used to 
measure NFκB signaling (Cell Signaling Technologies, 
Cat. #6956, #3033, and #3039, 1:500). IRS-1 signaling was 
detected using rabbit anti-phospho-IRS-1 (Ser1101) and 
rabbit anti-IRS-1 (Cell Signaling Technologies, Inc. Cat. 
#2385 and #2383, 1:500). cJun signaling was detected by 
rabbit anti-p-cJun (Ser73), Rb anti-p-cJun (Thr91) or Rb 
anti-cJun 60A8 (Cell Signaling Technologies, Cat. #9164, 
#2303, #9165, 1:500). Rabbit anti-PPARα (Abcam Inc. 
Cat. #24509,1:1000), rabbit anti-PPARβ/δ (Abcam Inc. 
Cat. #8937, 1:500), and rabbit anti-PPARγ (Cell Signaling 
Technologies, Inc. Cat. #2443, 1:500) were used to meas-
ure protein expression of the PPAR isoforms. MuRF2 
protein expression was detected by goat anti-MuRF2 
(Abcam Inc. Cat. #4387, 1:1000). Primary antibodies were 
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diluted in 5% milk or bovine serum albumin and incu-
bated at 4°C overnight. HRP-labeled secondary antibod-
ies against mouse (Sigma #A9917, 1:10,000), goat (Sigma 
#A4174, 1:10,000), and rabbit (Sigma #A9169, 1:5,000) 
were used to detect the primary antibodies diluted in 1× 
TBS-T and incubated 1  h at room temperature. Mouse 
anti-β-actin (Sigma, Inc., Cat. #A2228, 1:4,000) and 
mouse anti-GAPDH (Sigma, Inc., Cat. #G8795, 1:4,000) 
were used as a loading controls throughout. Second-
ary antibody HRP was detected using ECL Select (GE 
Healthcare, Cat. #RPN2235) and imaged using the Multi-
Doc-it Imaging System (UVP, LLC Ultra-violet Products, 
Ltd., Upland, CA, USA).
Immunoprecipitation studies
HEK293 cells were cotransfected with p3XFlag-
PPARγ1 and pcDNA3.1-HA-MuRF2 or pcDNA3.1-HA-
MuRF2ΔRing DNA plasmids. After 28 h of transfection, 
cells were lysed using RIPA buffer (Sigma, Inc., Cat. 
#R0278). Protein concentration was determined using 
Bio-Rad DC Protein Assay. 60 μl EZview Red Anti-Flag 
M2 Affinity Gel beads (Sigma, Inc., Cat. #F2426) were 
washed twice using 1× TBS, after the addition of 250 μg 
protein lysates, samples were gently agitated on a roller 
shaker overnight at 4°C. After three washes with 1xTBS, 
the proteins were eluted by 30  μl of 2× LDS Sample 
Buffer (NuPAGE LDS Sample Buffer, Lot#1452697) and 
boiled for 5  min at 100°C. Samples were analyzed by 
immunoblotting.
Total O‑GlcNAc expression
Total O-GlcNAc expression was determined by SDS-
PAGE as previously described [32], using anti-O-GlcNAc 
(RL-2, Santa Cruz Biotechnology, Santa Cruz CA) on 
PVDF blocked with 1% bovine serum albumin dissolved 
in TBS-T solution for 20 min, followed by an overnight 
incubation with O-GlcNAc antibody (1:1,000) at 4°C. 
Secondary antibody (goat-anti-mouse IgG-HRP, Santa 
Cruz Biotechnologies, Santa Cruz CA; 1:4,000) incubated 
for 1  h at room temperature, washed with TBS-T, then 
visualized with enhanced chemiluminescence (ECL) on 
the ChemiDoc™ XRS+ system with Image Lab™ Soft-
ware v2.0 (Bio-Rad Laboratories, Hercules CA, USA). 
Total O-GlcNAcylation (per lane) was quantified by the 
adjusted percentage volume—intensity units of pixels 
of band  ×  mm2—after background subtraction using 
Quantity One Software v4.6.9 (Bio-Rad Laboratories, 
Hercules CA, USA), and normalized to β-actin (Abcam, 
Cambridge MA, USA).
In vitro ubiquitination assay
Human recombinant GST-E1 (50 nM, Boston, Biochem, 
Cambridge, MA, Cat. #E-306), human recombinant 
UbcH5c/UBE2D3 (2.5  μM, Boston Biochem, Inc., 
Cambridge, MA, USA, Cat. #E2-627), human recom-
binant ubiquitin (250  μM, Boston Biochem, Inc., Cat. 
#U-100H), human MuRF2 recombinant protein (1  mg, 
LifeSensors, Cat. #UB305, Malvern, PA, USA), human 
PPAR-α, -β, and -γ recombinant protein (500 ng, Sigma-
Aldrich, Inc., St. Louis, MO, USA, Cat. #SRP2043, Cat. 
#SRP2044, and Cat. #SRP2045, respectively) were added 
to reaction buffer (50  mM HEPES, pH 7.5) containing 
5  mM MgATP solution (Boston Biochem, Inc., Cat. 
#B-20) and 0.6 mM DTT then incubated at 37°C for 1 h. 
The reaction was stopped by adding SDS-PAGE sample 
buffer and heating, then resolved on a 4–12% Bis–Tris 
gel with MOPS running buffer (Invitrogen Corp.) and 
transferred to PVDF membranes for immunoblotting 
with goat polyclonal anti-MuRF2 antibody (Abcam, 
Cat. #Ab4387), rabbit polyclonal anti-PPARα antibody 
(Abcam, Cat. #Ab24509), rabbit polyclonal anti-PPARβ 
antibody (Millipore, Cat. #AB10094), or rabbit poly-
clonal anti-PPARγ antibody (Cell Signaling Technology, 
Cat. #2443).
Non‑targeted metabolomics determination by GC–MS 
Instrumentation
Cardiac tissue was flash frozen with liquid nitrogen 
cooled in a biopress, a fraction weighed (~25–30  mg 
weight), finely ground, and added to fresh 50% acetyl-
nitrile, 50% water, and 0.3% formic acid at a stand-
ard concentration of 25  mg/475 mcl buffer, then fully 
homogenized on ice for 10–25 s and placed on dry ice/
stored at −80°C. Samples were “crash” deprotonized by 
methanol precipitation and spiked with D27-deuter-
ated myristic acid (D27-C14:0) as an internal standard 
for retention-time locking and dried. The trimethylsi-
lyl (TMS)-D27-C14:0 standard retention time (RT) was 
set at *16.727  min. Reactive carbonyls were stabilized 
at 50°C with methoxyamine hydrochloride in dry pyri-
dine. Metabolites were made volatile with TMS groups 
using N-methyl-N-(trimethylsilyl) trifluoroacetamide 
or MSTFA with catalytic trimethylchlorosilane at 50°C. 
GC/MS methods generally follow those of Roessner 
et al. [33], Fiehn et al. [34], and Kind et al. [35], which 
used a 6,890  N GC connected to a 5,975 Inert single 
quadrupole MS (Agilent Technologies, Santa Clara, 
CA, USA). The two wall-coated, open-tubular (WCOT) 
GC columns connected in series are both from J&W/
Agilent (part 122–5512), DB5-MS, 15  m in length, 
0.25  mm in diameter, with an 0.25-lm luminal film. 
Positive ions generated with conventional electron-
ionization (EI) at 70 eV are scanned broadly from 600 
to 50 m/z in the detector throughout the 45 min cycle 
time. Data were acquired and analyzed as previously 
described [36, 37].
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Statistical analysis
Sigma Plot 11.0 and Prism 6.0f  were used to plot and sta-
tistically analyze data. Depending upon the experimental 
design, several statistical tests were applied to the studies. 
Student’s t test or One Way ANOVA followed by Holm-
Sidak pairwise post hoc analysis was performed, indi-
cated in the figure legends. Significance was determined 
as p < 0.05. Values are expressed as mean ± SE. Statistical 
analysis on metabolomics data was performed as previ-
ously described [36, 37]. Metaboanalyst (v2.0) run on 
the statistical package R (v2.14.0) used metabolite peaks 
areas (as representative of concentration) [38, 39]. These 
data were first analyzed by an unsupervised principal 
component analysis (PCA), which identified the pres-
ence of the MuRF2−/− after 26 weeks high fat diet as the 
principal source of variance. To sharpen the separation 
between our three groups, data were next analyzed using 
a partial least squares discriminant analysis (PLS-DA) to 
further determine which metabolites were responsible 
for separating these two groups. The specific metabolites 
contributing most significantly to the differences identi-
fied by PLS-DA between MuRF2−/− and wildtype con-
trol group hearts were determined using the variable 
importance in projection (VIP) analysis in the Metabo-
analyst 2.0 environment. The metabolites that best dif-
ferentiated the groups were then individually tested using 
the Student’s t-test (Microsoft Excel 2011, Seattle, WA, 
USA). The VIP and t test significant metabolites were 
matched to metabolomics pathways using the Pathway 
Analysis feature in Metaboanalyst 2.0. Heat maps of the 
metabolite data (individual and grouped) were generated 
using the GENE E software (http://www.broadinstitute.
org/cancer/software/GENE-E/index.html).
Results
We have recently identified that MuRF2, a muscle-spe-
cific ubiquitin ligase, is a critical factor that regulates 
cardiomyocyte size during development in concert with 
MuRF1 [40]. MuRF2 has also been described as the effec-
tor protein in the Titin-nbr1-p62 complex that responds 
to mechanical changes in the sarcomere to inhibit trans-
activation of the nuclear transcription factor serum 
response factor (SRF) [41]. MuRF2’s regulation of the 
nuclear specific SRF was the first indication that MuRF2, 
found primarily in the cytoplasm, could regulate the 
activity of nuclear receptors, presumably through direct 
interaction, ubiquitination, and apparent nuclear export 
[41]. These findings led us to hypothesize that MuRF2 
similarly regulates other nuclear receptors critical to car-
diomyocytes. To test this, we used MuRF2−/− mice pre-
viously characterized without a cardiac or skeletal muscle 
phenotype [26]. However, we recently identified that 
MuRF2−/− hearts exhibited changes in metabolomics 
signatures, indicating that changes in metabolism are 
present despite any functional effect at baseline [37]. 
We initially assayed isolated nuclei from MuRF2−/− 
hearts for their DNA-binding activity contributed by 
PPARα, PPARβ, and PPARγ as the PPARs have been best 
described in altering cardiac metabolism [42] and have 
been reported to be regulated by ubiquitination [43]. To 
our surprise, we found that MuRF2−/− hearts had sig-
nificantly increased PPAR activities, with increases in 
PPARα (+twofold), PPARβ (~1.6 fold), and PPARγ (over 
+fourfold) activities compared with sibling MuRF2+/+ 
control mice (Fig.  1a). These findings suggested that 
endogenous MuRF2 attenuated the activity of all three 
PPAR transcription factors found in cardiomyocytes. 
Since MuRF2 is an ubiquitin ligase and PPAR transcrip-
tion factors have been described with post-translational 
modification by ubiquitin, we hypothesized that MuRF2 
may regulate these PPAR transcription factors in a ubiq-
uitination-dependent manner.
The pathogenesis of diabetic cardiomyopathy involves 
the enhanced activation of PPAR transcription fac-
tors [44]. Diabetic cardiomyopathy is characterized 
by increased free fatty acid oxidation in parallel with 
cardiomyocyte insulin resistance [6]. Both the result-
ing increased fatty acid oxidation and insulin contrib-
ute to the decreased ability for the heart to switch away 
from fatty acid utilization to glucose [45]. Since cardiac 
MuRF2−/− mice exhibited enhanced PPAR activity, we 
hypothesized that the induction of diabetic cardiomyopa-
thy would result in both enhanced PPAR activity, result-
ing in significant cardiac dysfunction compared with 
wildtype mice. To test this hypothesis, we challenged the 
MuRF2−/− mice to a 60% high-fat diet, which reproduc-
ibly induces insulin resistance and diabetic cardiomyopa-
thy (Fig. 1b) [24].
After 26  weeks of high fat diet challenge, MuRF2−/− 
mice had significantly lower blood glucose compared with 
sibling wildtype controls but no differences in serum insu-
lin levels (Additional file  1: Figure  S1a). Serum triglycer-
ides were similarly elevated in MuRF2−/− and wildtype 
controls after 26  weeks of high fat diet (Additional file  1: 
Figure S1b). Increased cardiac MuRF2 protein levels were 
identified after high fat diet (Fig.  1c), paralleling MuRF2 
increases identified in human inflammatory dilated car-
diomyopathy (http://www.ncbi.nlm.nih.gov/geopro-
files/26614376) and coronary artery atherosclerosis (http://
www.ncbi.nlm.nih.gov/geoprofiles/16462729). MuRF2−/− 
hearts increased total weight more than wildtype controls 
in high fat diet challenge (Fig. 1d) in addition to having sig-
nificant increases in overall body weight at any 15, 22, and 
25 weeks of HFD (Fig. 1e). However, no significant changes 
were identified in gastrocnemius, soleus, or tibialis anterior 
muscles weights (Additional file 1: Figure S1c).
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Echocardiographic analysis of MuRF2−/− hearts at 
baseline found no deficits in function or differences in 
measurements (Fig. 2a; Table 1) as previously described 
[40, 46]. Significant deficits in heart function were iden-
tified in the MuRF2−/− hearts in as little as 6  weeks 
after the initiation of high fat diet (Fig.  2a, upper left 
a
b
M
uR
F2
/G
A
P
D
H
 D
en
si
to
m
et
ry
 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
MuRF2 
GAPDH 37KDa 
84KDa 
MuRF2+/+ 
High Fat  
Diet 26  
Weeks 
MuRF2+/+ 
Chow 
d
%
Ac
tiv
ity
R
el
at
iv
e
to
M
uR
F2
+/
+
0
50
100
150
200
250
300
*
0
20
40
60
80
100
120
140
160
180
200
%
Ac
tiv
ity
R
el
at
iv
e
to
M
uR
F2
+/
+
MuRF2+/+
0
100
200
300
400
500
%
Ac
tiv
ity
R
el
at
iv
e
to
M
uR
F2
+/
+
MuRF2-/-MuRF2+/+ MuRF2-/-MuRF2+/+ MuRF2-/-
Cardiac MuRF2 Protein
PPARα Nuclear DNA-Binding 
Activity in MuRF2-/- Hearts
PPARβ Nuclear DNA-Binding 
Activity in MuRF2-/- Hearts
PPARγ Nuclear DNA-Binding 
Activity in MuRF2-/- Hearts
MuRF2+/+
MuRF2-/-
B
od
y 
W
ei
gh
t (
g)
c
Ba
se
lin
e
6 W
ee
ks
12
 W
ee
ks
15
 W
ee
ks
22
 W
ee
ks
26
 W
ee
ks
High Fat Diet
(60% Fat)
or Chow
(E) Echocardiography
(H) Histology
(B) Blood Glucose
Tissue
(T/G) Triglycerides/Glycogen
(I) Immunoblot analysis
(R) RT qPCR mRNA
(M) Metabolomics analysis
**
**
E, T, G, 
I, R E, E, E, E,
E, H, T, 
G, R, I, M  
eHeart Weight/Tibia Length
0
100
200
300
400
500
MuRF2+/+
26 Wks
HFD
MuRF2-/-
26 Wks
HFD
*
MuRF2+/+
26 Wks
HFD
MuRF2+/+
26 Wks
Chow
Ba
se
lin
e
6 W
ee
ks
12
 W
ee
ks
15
 W
ee
ks
22
 W
ee
ks
25
 W
ee
ks
Time Post-High Fat Diet Initiated
MuRF2+/+  N=         10                    11                    12                          8                             10                              10
MuRF2-/-     N=         11                    11                    11                          9                             12                              12
Body Weight§
0
10
20
30
40
50
¶
¶
¶
¶
¶
¶
3
3
3
4
4
4
3
3
5
5
Fig. 1 Role of MuRF2 in regulating PPAR isoform activity and its role in high fat diet cardiac hypertrophy in vivo. Isolation of cardiac nuclei from 
MuRF2−/− and sibling wild type mouse hearts revealed increases in a PPAR∝, PPARβ/δ, and PPARγ DNA binding activity using PPRE-DNA as bait 
and ELISA detection of PPARα protein (N = 4/group). b Experimental design of high fat diet (60%)-induced cardiomyopathy. c High fat diet induces 
cardiac MuRF2 levels after 26 weeks HFD (N = 3/group). d Endogenous MuRF2 inhibits HFD-induced LV Mass and heart wet weights, as MuRF2−/− 
hearts have a significant increase in heart weight normalized to body weight and tibia length (N = 5/group). e Endogenous MuRF2, found in 
skeletal muscle and the heart does not affect overall body weight (N indicated below graph). Values expressed as Mean ± SE. Statistical analysis was 
performed using a Student’s t-test comparing MuRF2−/− and MuRF2+/+ groups. *p ≤ 0.001, **p < 0.01. §p < 0.05 by One Way ANOVA, ¶p < 0.05 
vs. MuRF2+/+ baseline by multiple comparisons. $p < 0.05 vs. time-matched MuRF2+/+ (Student’s t-test).
Page 8 of 24He et al. Cardiovasc Diabetol  (2015) 14:97 
a
e
(F
ol
d 
C
ha
ng
e)
 N
or
m
al
iz
ed
 to
 1
8S
 
βMHC
αMHC
 β
M
yo
si
n 
H
ea
vy
 C
ha
in
 (M
H
C
) 
S
ke
le
ta
l M
us
cl
e 
-A
ct
in
  
(F
ol
d 
C
ha
ng
e)
 N
or
m
al
iz
ed
 to
 1
8S
 
A
tri
al
 N
at
riu
re
tic
 F
ac
to
r (
A
N
F)
 
(F
ol
d 
C
ha
ng
e)
 N
or
m
al
iz
ed
 to
 1
8S
 
-M
yo
si
n 
H
ea
vy
 C
ha
in
 (M
H
C
) 
(F
ol
d 
C
ha
ng
e)
 N
or
m
al
iz
ed
 to
 1
8S
 
B
N
P 
(F
ol
d 
C
ha
ng
e)
 
N
or
m
al
iz
ed
 to
 1
8S
 
Sk.m. -actin
BNP
ANF
MuRF2-/- Challenged 26 weeks 60% High Fat Diet
c
d
MuRF2+/+
26 Wks High Fat Diet
MuRF2-/-
26 Wks High Fat Diet
Systolic Function§
E
je
ct
io
n 
Fr
ac
tio
n 
/ 
Fr
ac
tio
na
l S
ho
rte
ni
ng
 (%
)
Heart Weight/Body Weight
0.0
0.1
0.2
0.3
0.4
0.5
0.6
H
ea
rt 
W
ei
gh
t/B
od
y 
Le
ng
th
 (m
g/
g)
#
MuRF2+/+
High Fat Diet
26 Weeks 
5
5
6 6
6
6
6
6
6
6
6
6 6
6
6
6
6
6
6
6
5
5
**
**
0
2
4
6
8
10
0
2
4
6
8
10
12 #
*
#
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
#
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4 #
**
Ejection Fraction %
MuRF2+/+
MuRF2-/-
Fractional Shortening %
Anterior Wall Thickness in 
Diastole (AWTD)§
Posterior Wall Thickness in 
Diastole (PWTD)§
Left ventricular End-Systolic 
Dimension (LVESD)§
W
al
l T
hi
ck
ne
ss
 (m
m
)
W
al
l T
hi
ck
ne
ss
 (m
m
)
LV
 E
nd
-D
ia
st
ol
ic
 D
im
en
si
on
 (m
m
)
LV Mass/Body Weight§
MuRF2-/-
High Fat Diet
26 Weeks 
Baseline HFD 
MuRF2
-/- 
MuRF2
+/+ 
MuRF2
-/- 
MuRF2
+/+ 
Baseline HFD 
MuRF2
-/- 
MuRF2
+/+ 
MuRF2
-/- 
MuRF2
+/+ 
Baseline HFD 
MuRF2
-/- 
MuRF2
+/+ 
MuRF2
-/- 
MuRF2
+/+ 
Baseline HFD 
MuRF2
-/- 
MuRF2
+/+ 
MuRF2
-/- 
MuRF2
+/+ 
Baseline HFD 
MuRF2
-/- 
MuRF2
+/+ 
MuRF2
-/- 
MuRF2
+/+ 
LV
 M
as
s/
B
W
 (m
g/
g)
1
2
3
4
5
6
7
Ba
se
lin
e
6 W
ee
ks
12
 W
ee
ks
15
 W
ee
ks
22
 W
ee
ks
25
 W
ee
ks
0
20
40
60
80
100
Time Post-High Fat Diet Initiated
Ba
se
lin
e
6 W
ee
ks
12
 W
ee
ks
15
 W
ee
ks
22
 W
ee
ks
25
 W
ee
ks
Time Post-High Fat Diet Initiated
Ba
se
lin
e
6 W
ee
ks
12
 W
ee
ks
15
 W
ee
ks
22
 W
ee
ks
25
 W
ee
ks
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Time Post-High Fat Diet Initiated
MuRF2-/-
MuRF2+/+
Time Post-High Fat Diet Initiated
Time Post-High Fat Diet Initiated
M
uR
F2
+/
+
M
uR
F2
-/-
Baseline 6  Weeks HFD 26  Weeks HFDb
MuRF2-/-
MuRF2+/+
25
 W
ee
ks
Ba
se
lin
e
6 W
ee
ks
12
 W
ee
ks
15
 W
ee
ks
22
 W
ee
ks
25
 W
ee
ks
Ba
se
lin
e
6 W
ee
ks
12
 W
ee
ks
15
 W
ee
ks
22
 W
ee
ks
$
¶,$ ¶,$
$
¶,$ ¶,$
$
$
¶,$ ¶,$ ¶,$ ¶,$
¶ ¶
$
$
$ $
¶ ¶
$
¶
$
$
¶
$
¶
¶
¶ ¶
¶,$
¶
¶
¶¶,$
¶,$
¶,$
¶
¶,$
¶
¶ ¶,$ ¶
¶
MuRF2-/-
MuRF2+/+
MuRF2-/-
MuRF2+/+
MuRF2+/+  N=         10                       11                        12                          8                       10                         10
MuRF2-/-     N=         11                       11                        11                          9                       12                         12
MuRF2+/+  N=         10                       11                        12                          8                       10                         10
MuRF2-/-     N=         11                       11                        11                          9                       12                         12
MuRF2+/+  N=         10                       11                        12                          8                       10                         10
MuRF2-/-     N=         11                       11                        11                          9                       12                         12
MuRF2+/+  N=         10                       11                        12                          8                       10                         10
MuRF2-/-     N=         11                       11                        11                          9                       12                         12
MuRF2+/+  N=         10                       11                        12                          8                       10                         10
MuRF2-/-     N=         11                       11                        11                          9                       12                         12
0.0
0.5
1.0
1.5
2.0
2.5
Fig. 2 Analysis of MuRF2−/− hearts by conscious echocardiograpy, morphometrics, and heart failure-associated gene expression. a MuRF2−/− 
exhibit an accelerated heart failure by 6 weeks after the initiation of the high fat diet. b Representative 2D echocardiographic images from 
MuRF2−/− hearts at baseline and high fat diet challenge. c Endogenous MuRF2 inhibits HFD-induced LV Mass and heart wet weights, as 
MuRF2−/− hearts have a significant increase in heart weight normalized to body weight and tibia length (N = 5/group). d Representative 
gross histological analysis of MuRF2−/− hearts, found to have wall thinning and increased LV diameters by echocardiological analysis (N = 11 
MuRF2+/+, N = 12 MuRF2−/−, see Table 1 and panel a above). e RT-qPCR analysis of heart failure associated fetal gene expression in MuRF2−/− 
mice at baseline and after 26 weeks high fat diet challenge. Values expressed as Mean ± SE. A One Way ANOVA was performed on echocardio-
graphic studies between all groups, followed by Holm-Sidak (Multiple Comparisons vs. MuRF2 +/+ baseline only). A Student’s t test was then run 
to compare MuRF2−/− to wildtype control at the same time point. §p < 0.05 by One Way ANOVA, ¶p < 0.05 vs. MuRF2+/+ baseline by multiple 
comparisons. $p < 0.05 vs. time-matched MuRF2+/+ (Student’s t test). Statistical analysis of heart weight/body weight was performed using a Stu-
dent’s t test. RT-qPCR analysis analyzed by a One Way ANOVA followed by Holm-Sidak Multiple Comparisons (all pairwise comparisons) *p < 0.001, 
**p < 0.01, #p < 0.05.
Page 9 of 24He et al. Cardiovasc Diabetol  (2015) 14:97 
Ta
bl
e 
1 
Ec
ho
ca
rd
io
gr
ap
hi
c 
an
al
ys
is
 o
f M
uR
F2
−/
− 
he
ar
t f
un
ct
io
n 
be
fo
re
 a
nd
 a
ft
er
 h
ig
h 
fa
t d
ie
t c
ha
lle
ng
e
H
ig
h-
re
so
lu
tio
n 
tr
an
st
ho
ra
ci
c 
ec
ho
ca
rd
io
gr
ap
hy
 p
er
fo
rm
ed
 o
n 
co
ns
ci
ou
s 
M
uR
F2
−/
− 
an
d 
ag
e-
m
at
ch
ed
 w
ild
 ty
pe
 m
ic
e 
at
 b
as
el
in
e,
 6
, 1
2,
 1
5,
 2
2,
 a
nd
 2
6 
w
ee
ks
 h
ig
h 
fa
t d
ie
t. 
D
at
a 
re
pr
es
en
t m
ea
n 
± 
SE
M
. A
 O
ne
 W
ay
 
A
N
O
VA
 w
as
 p
er
fo
rm
ed
 b
et
w
ee
n 
al
l g
ro
up
s, 
fo
llo
w
ed
 b
y 
H
ol
m
-S
id
ak
 M
ul
tip
le
 C
om
pa
ris
on
s 
vs
. M
uR
F2
+/
+ 
ba
se
lin
e.
 A
 S
tu
de
nt
’s 
t t
es
t w
as
 th
en
 ru
n 
to
 c
om
pa
re
 M
uR
F2
−/
− 
to
 w
ild
ty
pe
 c
on
tr
ol
 a
t t
he
 s
am
e 
tim
e 
po
in
t.
H
R 
he
ar
t r
at
e,
 E
xL
VD
 e
xt
er
na
l l
ef
t v
en
tr
ic
ul
ar
 d
ia
m
et
er
, b
pm
 h
ea
rt
 b
ea
ts
 p
er
 m
in
ut
e,
 A
W
TD
 a
nt
er
io
r w
al
l t
hi
ck
ne
ss
 in
 d
ia
st
ol
e,
 A
W
TS
 a
nt
er
io
r w
al
l t
hi
ck
ne
ss
 in
 s
ys
to
le
, P
W
TD
 p
os
te
rio
r w
al
l t
hi
ck
ne
ss
 in
 d
ia
st
ol
e,
 P
W
TS
 
po
st
er
io
r w
al
l t
hi
ck
ne
ss
 in
 s
ys
to
le
, L
VE
D
D
 le
ft
 v
en
tr
ic
ul
ar
 e
nd
-d
ia
st
ol
ic
 d
im
en
si
on
, L
VE
SD
 le
ft
 v
en
tr
ic
ul
ar
 e
nd
-s
ys
to
lic
 d
im
en
si
on
, F
S 
fr
ac
tio
na
l s
ho
rt
en
in
g,
 c
al
cu
la
te
d 
as
 (L
VE
D
D
-L
VE
SD
)/
LV
ED
D
 ×
 1
00
, E
F%
 e
je
ct
io
n 
fr
ac
tio
n 
ca
lc
ul
at
ed
 a
s 
(e
nd
 S
im
ps
on
’s 
di
as
to
lic
 v
ol
um
e 
− 
en
d 
Si
m
ps
on
’s 
sy
st
ol
ic
 v
ol
um
e)
/e
nd
 S
im
ps
on
’s 
di
as
to
lic
 v
ol
um
e 
× 
10
0,
 N
D
 n
ot
 d
et
er
m
in
ed
.
§  
 p
 <
 0
.0
5 
by
 O
ne
 W
ay
 A
N
O
VA
.
¶  
 p
 <
 0
.0
5 
vs
. M
uR
F2
+/
+ 
Ba
se
lin
e 
by
 M
ul
tip
le
 C
om
pa
ris
on
s.
$  
 p
 <
 0
.0
5 
vs
. t
im
e-
m
at
ch
ed
 M
uR
F2
+/
+ 
(S
tu
de
nt
’s 
t t
es
t)
.
M
uR
F2
+/
+ 
Ba
se
lin
e,
 
N
 =
 1
0 
(1
)
M
uR
F2
−/
− 
Ba
se
lin
e,
 
N
 =
 1
1 
(2
)
M
uR
F2
+/
+ 
6 
w
ee
ks
 
H
ig
h 
Fa
t D
ie
t 
N
 =
 1
1 
(3
)
M
uR
F2
−/
− 
6 
w
ee
ks
 
H
ig
h 
Fa
t D
ie
t 
N
 =
 1
1 
(4
)
M
uR
F2
+/
+ 
12
 w
ee
ks
 
H
ig
h 
Fa
t D
ie
t 
N
 =
 1
1 
(5
)
M
uR
F2
−/
− 
12
 w
ee
ks
 
H
ig
h 
Fa
t D
ie
t 
N
 =
 1
2 
(6
)
M
uR
F2
+/
+ 
15
 w
ee
ks
 
H
ig
h 
Fa
t D
ie
t 
N
 =
 1
1 
(7
)
M
uR
F2
−/
− 
15
 w
ee
ks
 
H
ig
h 
Fa
t D
ie
t 
N
 =
 1
2 
(8
)
M
uR
F2
+/
+ 
22
 w
ee
ks
 
H
ig
h 
Fa
t D
ie
t 
N
 =
 1
0 
(9
)
M
uR
F2
−/
− 
22
 w
ee
ks
 
H
ig
h 
Fa
t D
ie
t 
N
 =
 1
2 
(1
0)
M
uR
F2
 +
/+
 
26
 w
ee
ks
 
H
ig
h 
Fa
t D
ie
t 
N
 =
 1
0 
(1
1)
M
uR
F2
 −
/−
 
26
 w
ee
ks
 
H
ig
h 
Fa
t D
ie
t 
N
 =
 1
2 
(1
2)
AW
TS
 (m
m
)§
1.
79
 ±
 0
.0
4
1.
77
 ±
 0
.0
3
1.
82
 ±
 0
.0
7
1.
69
 ±
 0
.0
5
1.
88
 ±
 0
.0
8
1.
63
 ±
 0
.0
6$
1.
89
 ±
 0
.0
5
1.
68
 ±
 0
.0
6$
1.
87
 ±
 0
.0
7
1.
72
 ±
 0
.0
7
1.
85
 ±
 0
.0
9
1.
61
 ±
 0
.0
4$
LV
ED
D
 (m
m
)
2.
85
 ±
 0
.1
7
3.
27
 ±
 0
.1
6
3.
07
 ±
 0
.1
2
3.
05
 ±
 0
.0
8
2.
97
 ±
 0
.0
9
3.
02
 ±
 0
.0
9
3.
08
 ±
 0
.1
4
2.
94
 ±
 0
.1
2
2.
99
 ±
 0
.1
0
3.
05
 ±
 0
.1
2
3.
12
 ±
 0
.1
0
3.
34
 ±
 0
.0
5
PW
TS
 (m
m
)§
1.
65
 ±
 0
.0
4
1.
59
 ±
 0
.0
3
1.
66
 ±
 0
.0
5
1.
42
 ±
 0
.0
4$
1.
71
 ±
 0
.0
8
1.
42
 ±
 0
.0
2$
1.
72
 ±
 0
.0
9
1.
65
 ±
 0
.0
4
1.
65
 ±
 0
.0
4
1.
65
 ±
 0
.0
6
1.
65
 ±
 0
.1
2
1.
65
 ±
 0
.0
5
LV
 M
as
s 
(m
g)
§
10
5.
1 
± 
8.
1
12
3.
7 
± 
7.
6
12
1.
4 
± 
9.
4
11
1.
4 
± 
44
.2
12
0.
5 
± 
7.
2
10
3.
9 
± 
5.
5
15
3.
6 
± 
14
.5
¶
10
2.
7 
± 
4.
9$
15
3.
6 
± 
15
.4
¶
13
0.
2 
± 
7.
7¶
15
6.
6 
± 
12
.5
¶
12
5.
7 
± 
4.
1$
LV
 V
ol
;d
 (μ
l)
32
.5
 ±
 4
.7
44
.6
 ±
 4
.8
37
.9
 ±
 3
.8
37
.0
 ±
 2
.4
34
.6
 ±
 2
.6
36
.2
 ±
 2
.5
38
.7
 ±
 4
.0
34
.4
0 
± 
3.
6
37
.1
 ±
 3
.7
35
.4
 ±
 2
.9
39
.1
 ±
 3
.2
45
.5
 ±
 1
.7
LV
 V
ol
;s 
(μ
l)§
4.
0 
± 
0.
9
6.
5 
± 
0.
8
5.
5 
± 
0.
8
9.
6 
± 
0.
9¶
,$
5.
6 
± 
0.
7
9.
7 
± 
0.
8¶
,$
7.
3 
± 
1.
4
9.
1 
± 
1.
4¶
6.
7 
± 
1.
1
9.
8 
± 
0.
7¶
,$
12
.9
 ±
 1
.9
¶
14
.6
 ±
 1
.1
¶
BW
 (g
)§
20
.9
 ±
 1
.6
22
.9
 ±
 1
.2
24
.5
 ±
 1
.2
26
.2
 ±
 1
.4
29
.1
 ±
 1
.5
¶
32
.0
 ±
 1
.8
¶
31
.7
 ±
 1
.4
¶
34
.3
 ±
 1
.7
¶
33
.4
 ±
 1
.9
¶
36
.9
 ±
 2
.3
¶
36
.2
 ±
 2
.1
¶
39
.1
 ±
 2
.3
¶
H
R 
(b
pm
)§
60
9 
± 
19
59
0 
± 
18
67
1 
± 
8¶
63
6 
± 
8$
65
8 
± 
13
¶
65
4 
± 
14
¶
68
1 
± 
1¶
66
6 
± 
13
¶
66
5 
± 
11
¶
64
8 
± 
13
66
7 
± 
12
¶
66
8 
± 
9¶
Page 10 of 24He et al. Cardiovasc Diabetol  (2015) 14:97 
panel). MuRF2−/− hearts were significantly thinner than 
MuRF2+/+ hearts from 15–26  weeks of high fat diet 
feeding (Fig.  2a, upper middle panels, Fig.  2b, d). Both 
MuRF2−/− and wildtype mice experienced an equal 
progressive dilation over time on a high fat diet, evi-
denced by increases in LVESD (Fig.  2a, far right panel). 
MuRF2−/− hearts exhibited significant dysfunction as 
early as 6 weeks of HFD compared to MuRF2+/+ hearts 
(Fig.  2b). MuRF2−/− hearts were significantly larger 
than MuRF2+/+ hearts after 26  weeks high fat diet 
(Fig.  2b–d). Diabetic cardiomyocyte-related changes in 
myosin heavy chain gene expression were next investi-
gated to determine differences between groups. Compa-
rable increases in βMHC were seen in MuRF2−/− and 
wildtype hearts (Fig.  2e), consistent with previous stud-
ies identifying these increases [47]. MuRF2−/− car-
diac expression of skeletal muscle α-actin and αMHC 
were increased in chow control hearts compared to 
wild type mice, and MuRF2−/− skeletal muscle α-actin 
was significantly increased as compared to wild type 
mice after 26 weeks high fat diet (Fig. 2e). No difference 
existed in αMHC after 26 weeks of high fat diet in either 
MuRF2−/− or MuRF2  +/+  mice (Fig.  2e), although 
this is reported in other models of diabetic cardiomyo-
pathy [48, 49]. Brain natriuretic protein (BNP) mRNA 
was decreased in both MuRF2−/− and controls after 
26 weeks high fat diet feeding (Fig. 2e). Taken together, 
these studies identified that MuRF2−/− hearts failed 
sooner than MuRF2+/+ hearts, resulting in larger 
hearts, including LV wall thickness and heart weights 
after 26 weeks high fat diet challenge.
LV remodeling is a distinctive finding in the pathogene-
sis of diabetic cardiomyopathy. These changes include the 
development of fibrosis, resulting from the accumulation 
of extracellular collagen [50, 51]. Reduced MMP2 activity 
[52] and O-GlcNAcylation stimulated cardiac fibroblast 
collagen synthesis has been reported [53]. In this particu-
lar model, less than 2% fibrosis was identified through-
out the heart in MuRF2−/− and wildtype controls 
(Fig.  3a). However, MuRF2−/− hearts revealed a paral-
lel reduction in vimentin-positive fibroblasts (Fig.  3b). 
Throughout the course of the study, only one mouse died 
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at 21 weeks of high fat diet. This wildtype mouse, inter-
estingly, revealed almost 4% fibrosis (Additional file  2: 
Figure  S2c) with amorphous waxy infiltrates and leuko-
cyte infiltrates (Additional file  2: Figure  S2b) not seen 
in either MuRF2−/− or wildtype hearts after 26  weeks 
high fat diet (Additional file 2: Figure S2a). Overall, while 
MuRF2−/− hearts have significant increases in fibrosis, 
the total fibrosis is minimal and does not account for 
the large changes in cardiac size, dysfunction, and sug-
gests other non-structural signaling pathways likely are 
involved in the MuRF2−/− exaggerated cardiac dysfunc-
tion in diabetic cardiomyopathy.
Cardiac PPARα, PPARβ, and PPARγ1 have pivotal roles 
in the pathophysiology of diabetic cardiomyopathy [44]. 
Therefore, we next investigated the expression of car-
diac PPAR isoform regulated genes previously described 
in  vivo [54–56]. Gene expression of the cardiac PPARα 
target genes (not regulated by cardiac PPARβ i.e. glut1 
and cd36) (Fig.  4a), cardiac PPARβ target genes associ-
ated with glucose metabolism (not regulated by cardiac 
PPARα, i.e. glut4, pfk, acc1, mcad, and lcad) (Fig.  4b, 
c), and cardiac PPARγ1-regulated cardiac genes (i.e. 
acox1, adrp, cpt1b, and pdk4) (Fig. 4d) were evaluated in 
MuRF2−/− mouse hearts. Notably, MuRF2−/− hearts 
challenged with high fat diet exhibited significantly 
increased levels of PPARα-regulated genes (Fig.  4a), 
PPARβ-regulated genes associated with fatty acid metab-
olism (Fig.  4c), and PPARγ1-regulated genes (Fig.  4d). 
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MuRF2−/− hearts did not differ from MuRF2+/+ hearts 
in PPARβ-regulated target genes associated with glucose 
metabolism (glut4 and pfk, Fig.  4c). Like the PPAR iso-
form activities assays of the MuRF2−/− heart nuclei 
demonstrated, MuRF2−/− hearts exhibited enhanced 
PPAR activities. At the mRNA level, MuRF2−/− hearts 
exhibited significant increases in PPARα compared with 
wildtype mice, but no differences in PPARβ or PPARγ1 
(Additional file 3: Figure S3).
Fatty acids are the primary fuel of the heart in addi-
tion to being ligands for the PPAR transcription factors. 
High fat diets have been reported to increase cardiac 
triglyceride content [57]. The increased storage fat (as 
myocardial triglyceride) that occurs in the development 
of type 2 diabetic cardiomyopathy has been hypoth-
esized as one mechanism that free fatty acids are toxic 
to the heart [58–60]. The mishandling of cardiac glyco-
gen is also a frequent manifestation of diabetic cardio-
myopathy [61]. We hypothesized that increased levels 
of fatty acid in the MuRF2−/− hearts could contribute 
to the enhanced heart failure they demonstrated in dia-
betic cardiomyopathy. Since MuRF2 has been reported 
in the heart and skeletal muscle, in addition to the liver, 
we measured cardiac triglycerides and glycogen after 
26  weeks of high fat diet to determine if alterations in 
these storage forms of fat and glucose could be contrib-
uting to the increased heart weight or dysfunction in 
the MuRF2−/− hearts (Fig. 5). Compared to the control 
feeding, both MuRF2−/− and MuRF2+/+ hearts had 
increased cardiac triglyceride levels (Fig.  5a). However, 
MuRF2−/− hearts did not have significantly different 
triglyceride levels compared with wildtype after 26 weeks 
high fat diet feeding. MuRF2−/− liver and skeletal mus-
cle after 26 weeks high fat diet feeding was similarly not 
significantly different from wildtype controls (Fig.  5a). 
MuRF2−/− hearts from dietary controls (chow) had 
significantly decreased cardiac glycogen compared with 
wildtype hearts (Fig. 5b). While MuRF2−/− hearts accu-
mulated significantly increased glycogen after 26  weeks 
high fat diet, the increases MuRF2−/− liver and skeletal 
muscle accumulated did not reach significance (Fig. 5b). 
Together, these studies illustrate that the MuRF2−/− 
hearts are able to store fat (as triglyceride), but have alter-
ations in glycogen storage capacity both at steady state 
(baseline) conditions and after high fat diet challenges. 
Akt and glycogen synthase kinase (GSK)-3β are reported 
to be  decreased in diabetic cardiomyopathy, along with 
increases in fibrosis and inflammation [48, 62].
Recent studies have demonstrated a role for PPAR 
activation in developing adiposity and weight gain 
in models of diabetes. In one study, treatment with 
rosiglitazone in mouse models of diabetes was shown 
to promote increases in cardiac size and enhanced 
fat volume [63]. Similarly, rosiglitazone side effects in 
patients have revealed increasing fat gain [64]. At base-
line, MuRF2−/− mice had comparable fat and lean 
body mass as wildtype controls (Fig. 5c). However, dur-
ing the development of insulin resistance, MuRF2−/− 
mice demonstrated significantly more fat mass at 6 and 
12  weeks of high fat diet, but no changes in lean body 
mass (Fig. 5c). While the specific mechanisms by which 
rosiglitazone regulates fat mass is not completely clear, 
the enhanced PPAR activities seen in MuRF2−/− mice 
may be one contributing factor to the accumulation of 
fat mass during which cardiac function is significantly 
worse than wildtype mice challenged in parallel with a 
high fat diet.
The post-translational modification of intracellular 
proteins by O-linked N-acetylglucosamine (O-GlcNAc) 
in diabetes is a result of the excess glucose that drives the 
reaction. O-GlcNAc, in concert with ubiquitin, mediates 
several aspects of diabetic cardiomyopathy [53, 65–68]. 
O-GlcNAc modified proteins impair cardiomyocyte cal-
cium cycling via its direct effects on phospholamban [68, 
69]. O-GlcNAcylation also blunts autophagy, down regu-
lates Nkx2.5 expression, and stimulates cardiac fibroblast 
collagen synthesis to mediate cardiac dysfunction [53, 
65, 66]. Therefore, we measured the amount of O-Glc-
NAc proteins in MuRF2−/− heart, hypothesizing that 
the loss of MuRF2 cleared fewer O-GlcNAc-modified 
proteins, to mediate the enhanced cardiomyopathy seen 
in  vivo. Immunoblot analysis of O-GlcNAc-modified 
proteins in MuRF2−/− hearts demonstrated no differ-
ences from wildtype hearts when mice were fed a chow 
diet or 26  weeks of high fat diet (Additional file  4: Fig-
ure S4). While modest increases in O-GlcNAc levels were 
identified after 26 weeks of high fat diet, as expected with 
the observed hyperglycemia, differences in O-GlcNAc 
could did not appear to contribute to the  exaggerated 
MuRF2−/− cardiac dysfunction.
Since NF-κB signaling, defective insulin signaling, JNK 
signaling, and alterations in autophagy have been impli-
cated in the pathogenesis of diabetic cardiomyopathy 
[19, 70–72], we next determined if MuRF2−/− hearts 
had alterations in these processes that may explain their 
more severe phenotype. After 26 weeks of high fat diet, 
MuRF2−/− hearts did not exhibit enhanced NF-κB activ-
ity (determined by p-p65 western blot), decreased IRS-1 
signaling (determined by p-IRS-1 western blot), or alter-
nations in JNK signaling (determined by p-cJun) (Addi-
tional file  5: Figure  S5a). Similarly, measures of cardiac 
autophagy in MuRF2−/− hearts after high fat diet did 
not differ from wildtype controls, including autophagy 
flux (LC3II/LC3I proteins ratio post-bafilomycin treat-
ment by western blot), p62, or VPS34 protein levels by 
western blot (Additional file 5: Figure S5b). These studies 
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demonstrated that the more severe MuRF2−/− phe-
notype was not due to alterations in NF-κB, insulin, or 
JNK signaling or reductions in autophagy that have been 
reported to result in more severe diabetic cardiomyopa-
thy [19].
Evidence from a variety of cell culture studies have 
implicated ubiquitin as a post-translational modifier of 
PPAR transcription factors and their coreceptors/co-
activators [43]. These have been in liver, lung, fibroblast, 
adipocytes, and macrophage (as recently reviewed [43]). 
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These studies have found that the ubiquitin-mediated 
inhibition of PPAR isoforms PPARα, PPARβ, and PPARγ 
are: 1) ligand-dependent (ligand is required for ubiqui-
tination and/or degradation to occur); and 2) the ratio 
of ubiquitin ligase (e.g. MDM2 [73]) determines acti-
vation (e.g. MDM2:PPARα ratio  <  1) or inhibition (e.g. 
MDM2:PPARα  >  1 [73]). Since considerable evidence 
shows that MuRF2−/− hearts enhance PPAR-activity 
suggesting that endogenous cardiac MuRF2 inhibits PPAR 
activities by nuclear PPRE-binding (Fig.  1a) and PPAR-
regulated gene expression (Fig.  4), we next focused on 
how the muscle-specific ubiquitin ligase MuRF2 might 
exert its inhibitory effects based on our current knowl-
edge of how ubiquitin regulates PPAR in cancer cells.
Like other ubiquitin ligases, MuRF2 interacts with 
a number of protein  substrates. Notably, MuRF2 and 
MuRF1 redundantly interact with  roponin-I (TnI), TnT, 
myosin light chain 2, and T-cap (telethonin) in yeast two-
hybrid studies [74]. Unlike MuRF1, MuRF2 has not been 
shown to degrade any of these substrates (as recently 
reviewed [75] ). But critical regulation of microtubule, 
intermediate filament, and sarcomeric M-line stabil-
ity during striated muscle development [22] and regula-
tion of E2F activity [40]. Understanding that high fat diet 
induced MuRF2 expression, we next identified PPARα, 
PPARβ, and PPARγ1 (as the PPARγ2 isoform is restricted 
to adipocytes) (Fig.  6a). Interestingly, in steady state 
conditions, cardiac PPARα and PPARα protein levels in 
MuRF2−/− mice did not differ compared with wildtype 
controls. However, PPARγ1 levels were slightly (and sig-
nificantly) increased at baseline (Fig. 6a, far right). After 
challenge with PPAR ligands (free fatty acids from high 
fat diet) for 26 weeks, no differences in MuRF2−/− car-
diac PPARα and PPARγ1 were identified by immunob-
lot analysis, but a significant increase in PPARβ protein 
expression was identified (Fig. 6a). Taken together, these 
studies illustrate that the steady state levels of cardiac 
PPARα and PPARγ1 isoforms are not affected by the pres-
ence of MuRF2 or its increase (Fig. 1c) after high fat diet 
challenge. Moreover, these results suggest that MuRF2’s 
changes in PPARα and PPARγ1 activities could be due 
to one of the multiple non-canonical post-translational 
modifications by ubiquitin (e.g. mono-ubiquitination) 
that are not associated with proteasome dependent and 
degradation. How MuRF2 is regulating PPARβ without 
being able to ubiquitinate it directly (Fig.  6f ) is unclear. 
But the mechanism would be indirect include the pos-
sibility that MuRF2 it targeting the inhibition of a yet to 
be determined ubiquitin ligase(s) that normally degrades 
PPARβ. For example, PPARβ in cancer cells (HEK293 
and NIH3T3) is ubiquitinated and degraded in a ligand 
(GW501516)-dependent manner [76]. While the iden-
tification of the ubiquitin ligase targeting PPARβ is not 
known at this time, ubiquitin ligases degrading other 
isoforms (e.g. PPARγ) have been reported in adipocytes 
(MKRN1) [77]. Conversely, MuRF2 ubiquitination could 
be enhancing a de-ubiquitinase (DUB) that prevents pro-
teasome-mediated degradation by this unidentified E3(s).
We next sought to determine the underlying mecha-
nism by which endogenous MuRF2 exerted inhibition 
on PPAR-regulated genes (Fig.  4). Based in the limited 
work performed on PPAR ubiquitination (as recently 
reviewed [43]), we hypothesized that the ratio of MuRF2 
to the substrate may regulate whether the protein was 
degraded in a proteasome-dependent manner, as pre-
viously reported in cancer with MDM2:PPARα ratios 
[73]. Increasing the MuRF2:PPARγ1 ratios resulted in a 
dose-dependent decrease in steady state protein levels, 
consistent with poly-ubiquitination and subsequent deg-
radation (Fig.  6b). To determine the role of the protea-
some in this process, we next repeated these experiments 
and found that the MuRF2-mediated decrease in PPARγ1 
could be prevented by adding the proteasome inhibitor 
MG132 (Fig.  6d). Since previous studies have reported 
that ubiquitin ligase mediated proteasome degrada-
tion of PPARs is ligand dependent (as recently reviewed 
[43]), we next repeated these studies in the presence and 
absence of PPARγ ligand rosiglitazone, demonstrating 
that MuRF2’s dose-dependent degradation of PPARγ1 
was ligand dependent (Fig. 6d). To establish that MuRF2 
interacts with PPARγ1, we performed immunoprecipita-
tion studies by co-transfecting cells with HA-MuRF2 or 
HA-MuRF2ΔRing (lacking the ubiquitin ligase region) 
and FLAG-PPARγ1 (Fig.  6c). Immunoprecipitating 
PPARγ1, we identified that MuRF2 bound PPARγ1 by 
immunoblots (Fig.  6c). Unexpectedly, MuRF2ΔRing did 
not bind PPARγ1 in parallel studies suggesting MuRF2’s 
Ring Finger domain has structural importance in the 
interaction with PPARγ1.
In vivo, the cardiac MuRF2 protein levels increased 
~30% in wild type mice (Fig. 1c), while steady state lev-
els of PPARα, PPARβ, and PPARγ1 were either increased 
(PPARα, PPARγ1) or unchanged (PPARβ) in wildtype 
mice in response to 26 weeks of high fat diet compared 
to chow-fed wildtype controls (Fig. 6a). With no evidence 
that cardiac MuRF2 affected steady state PPARγ1 iso-
form protein levels yet inhibited PPARγ1 activity in vivo 
(MuRF2−/− hearts had enhanced PPARγ1 activities), 
we next tested how MuRF2 may be inhibiting PPARγ1 
mechanistically. Specifically, we wanted to determine 
why the physiological relevance of MuRF2-mediated 
degradation (with MuRF2:PPARg1 at levels 10:1) in vivo 
did not appear relevant in the context of diabetic car-
diomyopathy. The experimental studies indicating that 
high MuRF2:PPARγ1 ratios resulted in ligand-depend-
ent proteasome degradation may be relevant in other 
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Fig. 6 The ratio of MuRF2 to PPARγ1 determines the ubiquitin post-translational modification and ligand-dependent protein levels. a Immuno-
blot analysis of cardiac LV PPARα, PPARβ, and PPARγ1 levels normalized to GAPDH. N = 3/group. b Increasing MuRF2 results in a PPARγ1 ligand 
(Rosiglitazone)-dependent decrease in PPARγ1 in vitro 24 h after transfection. HEK293 cells were co-transfected with MuRF2 and PPARγ1 (as 
indicated below graph). After 24 h, 1 microM Rosiglitazone was added overnight and cells harvest at 48 h. *p < 0.05 vs. MuRF2:PPARγ1 ratio of 1:1 
without Rosiglitazone. c Immunoprecipitation studies identifying MuRF2 interaction with PPARg1. HEK293 cells were transfected p3XFlag-PPARγ1 
(or p3XFlag-Empty vector), pcDNA3.1-HA-MuRF2p50a (or HA-MURF2ΔRing) and immunoblotted for MuRF2 (anti-HA). d Left Proteasome inhibition 
with MG132 prevents MuRF2’s degradation of PPARγ1 in a Right ligase-dependent (Ring Finger-dependent) manner. HEK293 cells transfected with 
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unless otherwise indicated. Immunoblot for MuRF2 illustrates auto-ubiquitination (=MuRF2 activity) present in the same reaction as mono-ubiqui-
tination (PPARα) and poly-ubiquitination (PPARγ1). Values expressed as Mean ± SE of three independent experiments. A one-way ANOVA was per-
formed to determine significance, followed by a Holm-Sidak pairwise comparison to determine significance between groups. #p < 0.05, **p < 0.01.
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disease processes where MuRF2 levels are increased 
more in  vivo. However, such a disease process has not 
been described to date. Therefore, we focused our stud-
ies of MuRF2-mediated ubiquitination of PPAR iso-
forms using ratios of 2:1 (Fig.  6e–g). Whereas, MuRF2 
did not appear to add poly-ubiquitination leading to 
degradation, MuRF2 drove multi-mono-ubiquitination 
on PPARα and PPARγ1. Specifically, MuRF2 di-mono-
ubiquitinated PPARα, while adding ~four ubiquitin 
moieties to PPARγ1 (Fig.  6e, g, respectively). PPARβ, 
however, was unexpectedly not modified by ubiquitin at 
all in  vitro. These studies add perspective to our initial 
findings that endogenous cardiac MuRF2 had the great-
est regulation of PPARγ, with MuRF2−/− hearts exhibit-
ing 400%+ PPARγ activity found in the sibling wildtype 
hearts (Fig.  1a, far right). Endogenous MuRF2 similarly 
had the next most inhibition of PPARα, with MuRF2−/− 
hearts exhibiting ~250% PPARα activity found in sibling 
wildtype hearts (Fig. 1a, far left). Quite surprising was the 
finding that MuRF2 did not ubiquitinate PPARβ (Fig. 6f ), 
despite MuRF2 hearts exhibiting 80% more activity than 
wildtype controls (Fig. 1a, middle).
To gain more insight on how MuRF2 may be inhibit-
ing transcriptional activity by ubiquitination, we next 
performed nuclear localization studies using confo-
cal microscopy (Fig.  7). In control cells, we found that 
PPARγ1 could be found in both the nucleus and cytosol, 
with most cells having primarily nuclear localization 
(81%) (Fig.  7a). Increasing MuRF2 (2:1 ratio of PPARγ1 
transfected) interestingly resulted in an increase in the 
“perinuclear” localization of PPARγ1 (Fig.  7b). Notably, 
MuRF2 co-localized to these perinuclear regions (Fig. 7b). 
Parallel studies using the MuRF2 without its ubiquitin 
ligase activity (ΔRING-MuRF2) abrogated the perinu-
clear targeting of PPARγ and colocalization with MuRF2 
(Fig.  7c). Since we demonstrated that MuRF2, but not 
MuRF2ΔRing, bound to PPARγ1 (Fig.  6c), these studies 
indicates that MuRF2 regulation of PPARγ1 location may 
lie in its ubiquitin ligase activity and/or through some 
structural role required for interaction since MuRF2’s 
Ring Finger domain is required to bind PPARγ1 (Fig. 6c). 
Taken together, these studies suggested that MuRF2 tar-
gets an ubiquitin-mediated regulation of PPARγ1 activity 
by altering its localization within the nucleus, paralleling 
recent studies demonstrating autophagic sequestration of 
receptors in the endoplasmic reticulum and nucleus [78].
By non-targeted metabolomics analysis, MuRF2 hearts 
had significant decreases in taurine, myoinositol, and 
four metabolites involved in malate-aspartate shuttle 
(glycerol-1phosphate, urea, malic acid, and phosphoric 
acid) [37]. In the present study, we similarly analyzed 
MuRF2−/− hearts using non-targeted metabolomics 
analysis after 26 weeks of high fat diet (Fig. 8). The separa-
tion of MuRF2−/− hearts from wildtype was clear using 
b
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a
81.03% (47/58) 18.97% (11/58)
14.71% (10/68) 85.29% (58/68)
94.32% (5/88) 5.68% (83/88)
DAPI MuRF2(anti-HA)
PPARγ1
(anti-FLAG) Merged
Nuclear only,
N>C
Cytosol/Perinuclear,
C>N
FLAG-PPARγ1 only
FLAG-PPARγ1 + HA-MuRF2
FLAG-PPARγ1 + HA-∆RING-MuRF2
Nuclear only,
N>C
Cytosol/Perinuclear,
C>N
Nuclear only,
N>C
Cytosol/Perinuclear,
C>N
HL-1 Cells
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Principal Components Analysis (PCA) (Fig.  8a) as well 
as Partial Least Squares Discriminant Analysis (PLS-DA) 
and Variable Interdependent Parameters (VIP) analysis 
(Fig. 8b). Among all of the annotated metabolites (Fig. 8c), 
the VIP significant analytes detected were taurine, sucrose, 
glyceric acid, 3-hydroxyflavone, pantothenic acid, and glu-
tamic acid, among others (Fig.  8b). Enrichment analysis 
identified the (1) urea cycle; (2) aspartate metabolism; and 
(3) taurine and hypotaurine metabolism to be the highest 
fold enriched by metabolite sets (Fig. 8d). Based on loca-
tion, the mitochondria, peroxisome, and lysosome were 
the most enriched (Fig. 8e). Pathway analysis identified (1) 
taurine and Hypotaurine metabolism; (2) glycine, serine, 
and threonine metabolism; and (3) alanine, aspartate, and 
a
c
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e
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glutamate metabolism as the pathways most significantly 
affected when both t test and VIP significant metabolites 
were analyzed (Additional file 6: Figure S6).
Discussion
While the present study demonstrates a role for the 
muscle specific ubiquitin ligase in regulating PPAR tran-
scription factors in the context of diabetes, the clinical 
implications of these findings are broader. Recent studies 
have identified reductions in MuRF2 in patients with dia-
betic ischemic heart failure (GEO ID: 87403976, http://
www.ncbi.nlm.nih.gov/geoprofiles?term=87403976). 
Rare MuRF2 mutations in patients with familial hyper-
trophic cardiomyopathy have also been identified that 
are associated with a greater LV wall thickness than those 
without MuRF2 mutations [79]. Genome wide identifica-
tion of SARS-CoV susceptibility loci using the collabora-
tive cross has identified MuRF2 as a susceptibility factor 
to SARS infection, including evidence that MuRF2−/− 
mice are more susceptible (R.S. Baric, personal commu-
nication and GEO accession no. GSE64660, http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64660). 
Taken together, these studies suggest a role for MuRF2 
in an increased susceptibility to disease. Given the grow-
ing evidence that PPARs have anti-inflammatory activity 
by competitively inhibiting NF-κB and AP1 (cJun/cFos) 
experimentally (recently reviewed by Lockyer et al. [80]), 
it is possible that reduced (or ablated) MuRF2 in patients 
may increase their susceptibility to infection in addition 
to diabetes as we demonstrate in the present study.
The dynamic regulation of PPAR transcription factor 
activity reflects the complexity found routinely in biol-
ogy. PPAR family transcription factors routinely partner 
with RXR to regulate transcription of target genes, but co-
factors such as PGC-1a enhance PPAR activity (induced 
by exercise) and mitochondrial biogenesis, which nuclear 
receptor corepressor 1 (NCOR1) antagonizes these activ-
ity (as recently reviewed by Fan and Evans) [81]. PPAR 
activity is also regulated by ligands which bind the ligand 
binding domain and include endogenously free fatty 
acids, eicosinoids, and environmental compounds [82]. In 
addition to the various co-complex partners that regulate 
PPARs, there are other transcription factors that compete 
with PPARs to regulate their activity, notably NF-κB, mak-
ing enhanced PPAR activity an anti-inflammatory state 
[80]. It is on top of this complexity that post-translational 
modification by ubiquitin and SUMO has been reported 
primarily in cancer cells, and recently by our group in car-
diomyocytes for the first time [83]. In our recent review 
on this topic, few ubiquitin ligases have been described, 
but ubiquitination and proteasome-dependent deg-
radation of PPAR as well as SUMOylation has been 
reported in PPARα, PPARβ, and PPARγ1 in primarily 
non-physiological cultured conditions. The report here 
of the first ubiquitin ligase regulating PPARγ1 by ubiquit-
ination in a physiological process and cardiac pathophysi-
ological process (diabetes) adds detail to a dimension of 
regulation we’ve just begun to understand.
These layers of complexity are apparent in the present 
study. While our initial studies revealed that MuRF2−/− 
hearts had enhanced PPARα, PPARβ, and PPARγ1 (most 
prominently PPARγ1) activity measured by binding of 
PPRE DNA (Fig.  1a). However, these enhanced activi-
ties were clearly not due to increased total protein lev-
els of PPARα and PPARγ1 (Fig. 6a). Similarly, PPARα and 
PPARγ1 were multi-mono-ubiquitinated as a mechanism 
to explain their inhibition (Fig.  6e, g), while PPARβ was 
not ubiquitinated by MuRF2 (Fig. 6f). Like previous stud-
ies from our laboratory, the nuclear localization after MuRF 
protein post-translational ubiquitination may be regulat-
ing this process with PPARγ1 (Fig.  7) [83]. However, the 
indirect regulation of PPARβ protein levels (enhanced in 
MuRF2−/− hearts) is complex. The increase in PPARβ 
protein levels is not transcriptionally regulated (Addi-
tional file  3: Figure  S3b), leading to our hypothesis that 
MuRF2 regulates PPARβ through complex post-trans-
lational mechanism(s) as described above (e.g. MuRF2 
degradation of E3(s) targeting PPARβ or MuRF2 enhanc-
ing DUBs targeting PPARβ). Similarly complexity may lie 
with MuRF2’s regulation of PPARα as PPARα mRNA lev-
els are enhanced in MuRF2−/− hearts throughout this 
study (Fig.  3a). The regulatory elements in the promoter 
region of PPAR include activator protein-1 (AP-1) and 
how MuRF2 may inhibit these proteins is not clear [84, 85]. 
MuRF2−/− mice have equivalent PPARγ1 protein (Fig. 6a) 
and PPARγ1 mRNA (Additional file 3: Figure S3c). How-
ever, MuRF2−/− hearts also have the most highly acti-
vated PPARγ1 activity by several measures (Figs.  1a, 4d), 
indicating that the strong post-translational multi-mono-
ubiquitination in  vitro (Fig.  6g) may be MuRF2’s primary 
mechanism of regulating PPARγ1 in vivo.
MuRF2 has previously been shown to regulate two 
nuclear transcription factors found in myocytes, paral-
leling its role in regulating nuclear PPAR isoforms in 
the present study. Initial studies investigating the role of 
MuRF2 in differentiated myocytes identified that MuRF2 
binds critical signaling regions of the giant protein titin 
(via titin kinase region), to interact and regulate the activ-
ity and localization of the nuclear transcription factor 
SRF [41]. However, cardiac MuRF2 did not appear to 
regulate SRF activity in vivo, when stimulated by known 
SRF activating pressure overload-induced cardiac hyper-
trophy [26], suggesting this regulation is disease con-
text specific. Subsequently, MuRF2 has been implicated 
in redundantly regulating (with MuRF1) other nuclear 
transcription factors implicated in developmental 
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physiological hypertrophy [40]. In both cases, no evi-
dence of MuRF2-mediated degradation was identified, 
consistent with the degradation-independent regulation 
of PPAR isoforms in the present study. The most com-
monly reported regulation of PPAR isoforms from the 
cancer literature has identified that post-translational 
modification with ubiquitin and SUMO appears to regu-
late PPAR most commonly to inhibit their regulation.
The post-translational regulation of PPAR by ubiqui-
tin has previously been identified in cancer cells. How-
ever, ubiquitin-regulation of PPARs in the heart has not. 
Similarly, specific ubiquitin ligases have not been iden-
tified in these processes prior to this identification of 
MuRF2. In contrast to prior studies where ubiquitina-
tion was ligand dependent and resulted in PPAR deg-
radation (as recently reviewed [43]), here we identified 
that the MuRF2:PPARγ1 ratio determined if degradation 
occurred (Fig.  6b) and that the physiologically relevant 
non-degradation of PPARα, PPARβ, and PPARγ1 (Fig. 6a) 
resulted from multi-mono-ubiquitination of PPAR iso-
form substrates (Fig. 6e, g).
The ubiquitin ligase:substrate ratio effects on ubiquit-
ination chain type has been studied extensively in cancer 
with MDM2’s regulation of p53 [86–90]. In these series 
of elegant studies, investigators identified that low lev-
els of MDM2 induced mono-ubiquitination and nuclear 
export of p53, whereas high levels of MDM2 promoted 
poly-ubiquitination and nuclear degradation of p53 [90]. 
In the context of stress, Li et al. endorsed the notion that 
non-stressed cells regulated p53 by mono-ubiquitination 
to circumvent the more extensive investment in energy 
the poly-ubiquitination and degradation require [89]. 
Conceptually, this increased energy expenditure may 
be worthwhile during stress considering that the big-
ger degradation response leads to apoptosis, whereas 
mono-ubiquitnation does not [89]. These studies also 
highlight the highly dynamic process of transcription 
factor regulation at the post-translational level [87]. 
Subsequent studies identified that SUMOylation, a pro-
cess paralleling ubiquitination, can regulate the strength 
of the MDM2-p53 interaction and participates in the 
nuclear export [88]. This process appears to involve the 
stepwise interplay between SUMOylation and ubiquit-
ination of p53 [86]. Very much like p53, all three PPAR 
isoforms are both SUMOylated and ubiquitinated, so 
future studies investigating the possible role of MuRF2-
regulation of PPAR isoform ubiquitination may take this 
into consideration. The requirement of SUMOylation for 
ubiquitination to occur may also explain MuRF2’s appar-
ent regulation of PPARβ activity (Fig. 1a, middle frame) 
in  vivo, but absence of PPARβ ubiquitination in  vitro 
(Fig.  6f ) with demonstrable MuRF2 activity but lack of 
SUMO and/or other interacting proteins.
Another unexpected finding in the present study is 
the multi-mono-ubiquitination of PPARα and PPARγ1 
proteins identified in the in  vitro ubiquitination assays 
(Fig.  6e, g, respectively). In cancer cells, the ubiquitin 
ligase 14ARF has been reported to di-ubiquitinate p53 
in a manner which inhibits MDM2, another 14ARF sub-
strate [91]. Like previous reports of multi-ubiquitinated 
(e.g. mono- and di-ubiquitination) substrates [92–94], 
di- or tri-ubiquitination of PPAR does not lead to its deg-
radation in the physiological conditions. Interestingly, 
14ARF induces p53-dependent SUMOylation in its tar-
get substrates, including MDM2 and NPM, in addition to 
ubiquitinating the protein [91]. MuRF2’s multi-ubiquit-
ination may offer additional clues into the complex regu-
lation of cardiac PPAR isoforms previously unknown.
We previously identified that MuRF2−/− hearts exhib-
ited alterations in taurine, aspartic acid, and d-malic 
acid in vivo compared to strain-matched wildtype hearts 
[37]. In the present study, we expanded these findings in 
MuRF2−/− hearts after 26  weeks high fat diet to illus-
trate that differences in taurine, sucrose, glyceric acid, 
3-hydroxyflavone, pantothenic acid, and glutamic acid 
(Fig. 8b). Alternations in taurine and hypotaurine metab-
olite sets (Fig. 8d) in the MuRF2−/− hearts are interest-
ing given the emerging role of taurine on chronic heart 
failure. Taurine is an abundant amino acid that influ-
ences the heart’s response to stress. It is one of the most 
abundant amino acids in the left ventricle, acting as an 
osmoregulator to trigger osmotic preconditioning, a pro-
cess that activates Akt-dependent cytoprotective signal-
ing [95]. The loss of taurine can depress protein synthesis 
and reduce energy reserves after cardiac surgery and has 
been found to be preserved [96]. Specifically, taurine has 
been shown to attenuate oxidative stress and alleviate 
heart failure in diabetic rates [97]. Supplementation of 
taurine in patients with heart failure has been used clini-
cally [98, 99]. Our understanding of cardiac taurine biol-
ogy is limited, but regulation of taurine by the taurine/
Na+ symport is believed to play an important functional 
role in heart failure and replacement an emerging prac-
tice in Japan. It’s role in diabetic cardiomyopathy, in par-
ticular, has been found to reduce AGE, oxidized LDL by 
scavenging malondialdehyde, and hypochlorous acid and 
downstream HClO-dependent NO reduction [100].
At least three ubiquitin ligases, namely RNF5, TRAF6, 
and Nedd4 have been described as regulators of 
autophagy components ATG4B and Beclin1 in non-car-
diovascular systems [101]. With the growing appreciation 
of E3s in regulating autophagy and MuRF2’s interactions 
with the autophagy-related Nbr1, p62, and LC3 proteins 
during cardiac myofibril assembly and turnover [41, 102], 
it was surprising that MuRF2−/− cardiac autophagy was 
not affected differentially after the high fat diet challenge 
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(Additional file  5: Figure  S5b). Despite these provoca-
tive parallels, no previous studies of MuRF2’s regula-
tion of autophagic flux have been described, and in the 
present studies, the lack of endogenous MuRF2 did not 
affect autophagic flux after high fat diet challenge (Addi-
tional file  5: Figure  S5b). Similarly, steady state cardiac 
p62 protein levels were unaffected by the lack of endog-
enous MuRF2 (Additional file  5: Figure  S5b), indicat-
ing that cardiac MuRF2 may not have a role in cardiac 
autophagy or that other MuRF family proteins, such as 
MuRF1 which has been described in multiple processes 
[37, 40], are functionally redundant and is compensat-
ing in the MuRF2−/− model. As emerging evidence that 
autophagy plays a role in the pathogenesis of diabetic 
cardiomyopathy by clearing post-translationally modified 
proteins, such as advanced glycation end products and 
the severity of disease [19], targeting autophagy may offer 
one therapeutic pathway [103]. In the present study, we 
did not identify that endogenous MuRF2 was protective 
via this pathway, however.
A host of changes have been described in diabetic 
cardiomyopathy, characterized by cardiac hypertrophy, 
inflammation, fibrosis, and apoptosis due to altered insu-
lin signaling and calcium handling [104]. The MuRF fam-
ily ubiquitin ligases, including MuRF1 and MuRF2 have 
shown to be critical regulators of cardiomyocyte growth 
and atrophy. Specifically, both physiological and patho-
logical growth has been attributed to MuRF1 and MuRF2 
in the heart [40, 46, 105] and skeletal muscle [106], while 
MuRF1 regulation of cardiac [106] and skeletal mus-
cle atrophy [107, 108]. While the changes seen in dia-
betic cardiomyopathy are vast, including alternations in 
metabolism, structural proteins, signal transduction, and 
ion channels [109], the crucial role of enhanced PPAR 
signaling has been central to the pathogenesis of this dis-
ease downstream of altered insulin resistance [12, 44]. 
Regulation of PPAR activity, including post-translational 
modification-mediated regulation, is a process little 
understood in any cell type, including the cardiomyocyte. 
The findings of the current study implicate the first car-
diac specific ubiquitin ligase that functionally regulates 
PPAR isoform signaling, by ubiquitination, inhibiting a 
central pathway in the pathogenesis of disease. Since the 
regulation of PPARs are dynamic during the course of 
diabetic cardiomyopathy [110–113], these studies iden-
tify the role of MuRF2 in the pathogenesis of diabetic 
cardiomyopathy and its regulation of PPAR isoforms, 
including the post-translational inhibition of PPARγ1 
that is cardioprotective in vivo.
Conclusions
We describe the first mechanism by which an ubiquitin 
ligase inhibits multiple cardiac PPAR isoforms, to protect 
against high fat diet-induced diabetic cardiomyopathy. 
We identified that MuRF2 protein levels increase ~20% 
during the development of diabetic cardiomyopathy 
induced by high fat diet. Compared to littermate wildtype 
hearts, MuRF2−/− hearts exhibit an exaggerated diabetic 
cardiomyopathy, characterized by an early onset systolic 
dysfunction, larger left ventricular mass, and higher heart 
weight. MuRF2−/− hearts had significantly increased 
PPARα- and PPARγ1-regulated gene expression by RT-
qPCR, consistent with MuRF2’s regulation of these tran-
scription factors in  vivo. Recent studies have described 
MuRF2 mutations to contribute to the severity of familial 
hypertrophic cardiomyopathy. The present study suggests 
that the lack of MuRF2 activity, as found in these patients, 
can result in an exaggerated diabetic cardiomyopathy. 
These present studies also identify MuRF2 as the first 
ubiquitin ligase to regulate cardiac PPARα and PPARγ1 
activities in vivo via post-translational modification with-
out degradation and may represent a novel potential ther-
apeutic target against heart failure in diabetes.
Additional files
Additional file 1: Figure S1. Analysis of circulating total cholesterol, 
triglyceride, glucose, insulin, and muscle weight analysis at baseline and 
after 26 weeks high fat diet challenge. A. Fasting blood glucose and 
fasting serum insulin levels. B. Fasting total cholesterol and fasting serum 
triglyceride levels. C. Organ weights at 26 weeks high fat diet of gastroc-
nemius, soleus, and tibialis anterior. Values represent the mean ± SE (N 
indicated above bars). Values expressed as Mean ± SE. A one-way ANOVA 
was performed to determine significance followed by an all pairwise mul-
tiple comparison procedure (Holm-Sidak method). #p<0.05, *p<0.001.
Additional file 2: Figure S2. Histological analysis of MuRF2-/- mice. A. 
Representative H&E analysis of MuRF2-/- and MuRF2+/+ tissue. B. Single 
MuRF2+/+ heart from mouse found dead 21 weeks high fat diet reveals 
amorphous way infiltration (arrows) and rare leukocytes infiltrations (*). C. 
Analysis of Masson’s Trichrome stained slides of MuRF2+/+ heart revealed 
~3% fibrosis.
Additional file 3: Figure S3. mRNA analysis of cardiac PPAR isoform 
expression in MuRF2 -/- mice. Quantitative RT qPCR analysis of cardiac A. 
PPAR∝ mRNA B. PPARβ mRNA and C. PPARγ1 mRNA at baseline and 26 
weeks after high fat diet compared to sibling-matched wild type hearts. 
N=5/group. A one-way ANOVA was performed to determine significance 
followed by an All Pairwise Multiple Comparison Procedure (Holm-Sidak 
method). *p<0.001.
Additional file 4: Figure S4. Detection of cardiac O-GlcNac Protein 
modifications in MuRF2-/- mice after 26 weeks HFD challenge. A. Densi-
tometric analysis of O-GlcNac/βactin immunoblot (B). N=3/group. Values 
expressed as Mean ± SE. A one-way ANOVA was performed to determine 
significance followed by an All Pairwise Multiple Comparison Procedure 
(Holm-Sidak method). #p<0.05.
Additional file 5: Figure S5. Analysis of MuRF2-/- cardiac NF-κB, IRS-1, 
cJun signaling and autophagy. A. Immunoblot analysis of NF-κB, IRS-1, and 
cJun reveal no differences in MuRF2-/- and sibling wild type mice (N=3/
group). B. Analysis of autophagic flux post-Bafilomycin treatment prior to 
harvest did not detect differences in LC3II isoform, p62, or VPS34 protein 
levels. Values expressed as Mean ± SE. Statistical analysis was performed 
using a Student’s t-test. N=3/group. Significance determined as p<0.05.
Additional file 6: Figure S6. Pathway analysis of VIP and t-test signifi-
cant metabolites found in non-targeted metabolomics analysis of MuRF2-
/- hearts after high fat diet. N=3/group.
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